Anti-HMHA1/HA-1 antibody (C-Term) (STJ70047)

SKU:
STJ70047-100

Shipping:
Free Shipping
Current Stock:
Host: Goat
Applications: Pep-ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Goat polyclonal antibody anti-HMHA1/HA-1 (C-Term) is suitable for use in ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA
Purification: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Concentration: 0.5 mg/mL
Dilution Range: ELISA-antibody detection limit dilution 1:32000.
Storage Instruction: Store at-20°C on receipt and minimise freeze-thaw cycles.
Gene Symbol: ARHGAP45
Gene ID: 23526
Uniprot ID: HMHA1_HUMAN
Immunogen Region: C-Term
Accession Number: NP_036424.2
Specificity: To avoid confusion please note that this antibody is designed to recognise the whole protein as coded by NP_036424.2 and won t recognise the peptide found eluted from HLA-A*0201 molecules by den Haan et al (Science. 1998 Feb 13;279 (5353) :1054-7, PM
Immunogen Sequence: TLGSCRERQPEFV
Function Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
Protein Name Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1
Mhag Ha-1
Database Links Reactome: R-HSA-6798695
Reactome: R-HSA-8980692
Reactome: R-HSA-9013148
Reactome: R-HSA-9013149
Cellular Localisation Cytoplasm
Cell Projection
Ruffle Membrane
Alternative Antibody Names Anti-Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1 antibody
Anti-Mhag Ha-1 antibody
Anti-ARHGAP45 antibody
Anti-HMHA1 antibody
Anti-KIAA0223 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance